Introduction Lifelong anticoagulation is the cornerstone of the chronic thromboembolic pulmonary hypertension (CTEPH) treatment regardless of the additional pulmonary endarterectomy, balloon pulmonary angioplasty, or medical treatment alone. Aim of this study was to evaluate the rate of oral anticoagulant preferences and document direct oral anticoagulants’ (DOACs’) safety, efficacy in the CTEPH population. Methods Patients’ demographic data obtained from database between September 2011 and April 2018. In-hospital events, death, venous thromboembolism (VTE) recurrence, bleeding events and anticoagulant therapy transition were recorded. Results We reviewed 501 CTEPH patients who observed 9.0 ± 8.5 years. All-cause death, all bleeding, recurrent VTE was observed in 15.6%, 31% and 12%. Forty-one patients (8.2%) were diagnosed as inoperable. Of all, 15.2% of operable patients remained as residual. All-cause mortality rates were 13.8% (57 pts.) in the warfarin group as compared with 9.7% (13 pts.) in rivaroxaban group (HR: 1.61, 95% CI, 0.89–2.99; p: 0.11). Higher bleeding events occurred with warfarin group (27.1%) as compared with rivaroxaban (24.6%; HR: 1.28, 95% CI, 0.86–1.88; p: 0.22). Major bleeding was significantly higher with warfarin group (HR: 1.94, 95% CI, 1.05–3.62; p: 0.03). Subgroup analysis of all-cause death revealed that this significance dominated by the rate of death according to bleeding events; warfarin versus those seen with rivaroxaban (4.85% vs. 2.2%; HR: 4.75, 95% CI: 1.12–20.16; p = 0.03). The rate of recurrent VTE was found 8.9% in the rivaroxaban group, 10.9% in warfarin group (HR: 1.21, 95% CI, 0.64–2.23; p: 0.55). Conclusion DOACs could be a safe and effective alternative for lifelong anticoagulant therapy in CTEPH patients. Rivaroxaban produced similar rates of thromboembolism and non-relevant bleeding compared to those associated with warfarin. The main difference was found with major bleeding that it was mainly associated with the death rate according to major bleeding. Using DOACs might be a more reasonable way to prevent bleeding events without increasing thromboembolic risk.
Our findings suggest that SD blunts cardiovascular autonomic response, and consequences of this relation might be more pronounced in subjects who are exposed to sleeplessness regularly or in subjects with baseline cardiovascular disease.
Acute SD is associated with a reduction in LA passive emptying function in healthy adults. 3D-derived indices were sufficient to show subclinical diastolic dysfunction according to impairment in passive phase of LA ejection. Prospective large-scale studies are needed to enlighten this issue.
Our study demonstrated a high crossover rate (24%) of axillary artery and vein and a high degree of variation in the course of axillary vein. Small arterial bridges over the axillary vein were observed in 77% of the patients.
Purulent pericardial effusion, although rare, is a life-threatening condition usually produced by the extension of a nearby bacterial infection locus or by blood dissemination in the immune-suppressed subjects or in the course of cardiothoracic surgery. Because clinical features of purulent pericardial effusion are often nonspecific, it can cause delay in diagnosis. Therefore, a high index of suspicion is required for timely diagnosis and management. Herein, we describe a case of giant purulent pericardial effusion due to Streptococcus intermedius with the history of bronchiectasis and pneumonia, which was successfully treated with pericardiocentesis via parasternal approach, appropriate antibiotics, and pericardiectomy.
Objective: Erectile dysfunction (ED) is a common condition in patients with heart failure (HF), which impairs quality of life. Our
study aimed to compare those patients, who received traditional treatment with a diagnosis of HF and those who received angiotensin
receptor-neprilysin inhibitor (ARNI) treatment in addition to the current treatment, in terms of ED at the end of 6 months.
Patients and Methods: The study was planned as a single-center, prospective study. The study included 200 patients with heart
failure. The patients’ demographic, clinical, and echocardiographic characteristics were recorded, and an international ED scoring
questionnaire was applied. The participants in the study were divided into two groups: those who received ARNI treatment and those
who did not. After 6 months, the ED questionnaire was applied to the patients again and the groups were compared.
Results: The median age of the patients was 53 (years). The median ejection fraction (EF) value was calculated to be 30% and no
significant difference was found between the groups (p: 0.122). It was found that N-terminal pro-brain natriuretic peptide (NT-pro-
BNP) levels measured at the end of the 6th month were significantly lower in patients who had received ARNI treatment than in those
who had not (respectively, 245 pg/ml, 200 pg/ml; p: 0.003). In the analysis performed to detect the presence of ED, it was discovered
that the ED score change was significantly higher in the group that had received 6 months of ARNI treatment (p: 0.031) compared to
that in the group that had not (p: 0.031). When the ED sub-parameters were compared in terms of the 6-month change rate, it was
found that the ARNI group had a significant increase in terms of ED and sexual satisfaction scores, but no significant difference was
found in the other parameters (p: 0.001, p: 0.029).
Conclusion: Erectile dysfunction is more common in patients with heart failure compared to the rest of society and impairs quality of
life. In our study, it was determined that ED complaints decreased significantly in HF patients, who had received ARNI treatment for
6 months than in patients who had not.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.